Dentistry Medical News about ALL

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Acute lymphoblastic leukaemia: an unusual radiological presentation
Dentomaxillofacial Radiology , 06/02/09

Ali R et al. - A 14-year-old female patient attended Bristol Dental Hospital for an oral screening prior to undergoing a bone marrow transplant as treatment for her acute lymphoblastic leukaemia. Maxillofacial radiographs revealed multiple, well-defined, non-corticated radiolucent lesions throughout the vault of her skull and mandible. These radiological features (coupled with the patient's age) would have correlated with a diagnosis of Langerhans cell histiocytosis.

<< Previous
Implant-Retained Maxillary Overdentures on Milled Bar...

Next >>
Lip cancer in Western Australia, 1982–2006: a 25-year...

All-Trans Retinoic Acid-Induced Focal Myositis, Synovitis, and Mononeuritis
Journal of Clinical Rheumatology (JCR), 10/14/09 Relevance Score: 88%

HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk
Atherosclerosis, 10/08/09 Relevance Score: 88%

Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia
British Journal of Haematology, 10/05/09 Relevance Score: 88%

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors
Journal of Clinical Oncology, 11/13/09 Relevance Score: 87%

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V
Value in Health, 10/29/09 Relevance Score: 87%